Association Studies of HFE C282Y and H63D Variants with Oral Cancer Risk and Iron Homeostasis Among Whites and Blacks
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Sample Collection and Processing
2.3. Genotyping
2.4. Serum Iron Analysis
2.5. Statistical Analysis
3. Results
Oral Cases n (%) | Controls n (%) | p-value | |
---|---|---|---|
Whites | |||
Mean Age * | 60.1 ± 12.8 | 58.6 ± 13.3 | 0.22 |
Women | 59 (29.4) | 102 (33.4) | 0.31 |
Pack-years * | 41.8 ± 33.6 | 17.6 ± 29.0 | <0.01 |
Alcohol consumption | <0.01 | ||
Heavy drinkers | 58 (36.0) | 31 (11.7) | |
Moderate drinkers | 32 (19.9) | 34 (12.9) | |
Light drinkers | 21 (13.0) | 68 (25.8) | |
Non-drinkers | 50 (31.0) | 131 (49.6) | |
Missing | 40 | 37 | |
Blacks | |||
Mean Age * | 58.3 ± 10.4 | 58.3 ± 13.3 | 0.95 |
Women | 27 (27.0) | 49 (36.6) | 0.12 |
Pack-years * | 43.5 ± 36.2 | 18.4 ± 30.1 | <0.01 |
Alcohol | <0.01 | ||
Heavy drinkers | 45 (49.5) | 23 (15.8) | |
Moderate drinkers | 20 (22.0) | 15 (10.2) | |
Light drinkers | 11 (12.1) | 23 (15.8) | |
Non-drinkers | 15 (16.5) | 85 (58.2) | |
Missing | 9 | 12 |
Cases, n (%) | Controls, n (%) | OR (95% CI) * | |
---|---|---|---|
Whites | |||
rs1799945 (C>G), H63D | |||
CC | 144 (82.8) | 214 (79.6) | 1.00 (reference) |
CG + GG | 30 (17.2) | 55 (20.4) | 0.81 (0.49–1.33) |
rs1800562 (G>A), C282Y | |||
GG | 188 (94.0) | 280 (94.6) | 1.00 (reference) |
GA + AA | 12 (6.0) | 16 (5.4) | 1.12 (0.52–2.41) |
Blacks | |||
rs1799945 (C>G), H63D | |||
CC | 86 (91.5) | 116 (94.3) | 1.00 (reference) |
CG | 8 (8.5) | 7 (5.7) | 1.54 (0.54–4.41) |
rs1800562 (G>A), C282Y | |||
GG | 98 (98.0) | 129 (96.3) | 1.00 (reference) |
GA | 2 (2.0) | 5 (3.7) | 0.53 (0.10–2.77) |
rs1800562 (G>A), C282Y | |||
Biomarker | GG | GA + AA | p-value |
Iron (µg/dL) | 83.7 ± 28.2 | 109.4 ± 63.3 | 0.063 |
TIBC (µg/dL) | 397 ± 89.0 | 321 ± 37.2 | 0.007 |
Ferritin (ng/mL) | 166 ± 165 | 383 ± 248 | 0.058 |
Transferrin (%) | 22.0 ± 8.7 | 35.6 ± 22.9 | 0.023 |
rs1799945 (C>G), H63D | |||
Biomarker | CC | CG + GG | p-value |
Iron (µug/dL) | 84.0 ± 32.7 | 92.1 ± 21.4 | 0.357 |
TIBC (µg/dL) | 396 ± 89.6 | 390 ± 108 | 0.820 |
Ferritin (ng/mL) | 169 ± 170 | 183 ± 164 | 0.765 |
Transferrin (%) | 22.3 ± 10.3 | 25.6 ± 9.7 | 0.251 |
4. Discussion
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
Abbreviations
References
- Feder, J.N.; Gnirke, A.; Thomas, W.; Tsuchihashi, Z.; Ruddy, D.A.; Basava, A.; Dormishian, F.; Domingo, R., Jr.; Ellis, M.C.; Fullan, A.; et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996, 13, 399–408. [Google Scholar] [CrossRef] [PubMed]
- Feder, J.N.; Tsuchihashi, Z.; Irrinki, A.; Lee, V.K.; Lebron, J.A.; Watson, N.; Tsuchihashi, Z.; Sigal, E.; Bjrorkman, P.J.; Schatzman, R.C. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J. Biol. Chem. 1997, 272, 14025–14028. [Google Scholar] [CrossRef] [PubMed]
- Waheed, A.; Parkkila, S.; Zhou, X.Y.; Tomatsu, S.; Tsuchihashi, Z.; Feder, J.N.; Schatzman, R.C.; Britton, R.S.; Bacon, B.R.; Sly, W.S. Hereditary hemochromatosis: Effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc. Natl. Acad. Sci. USA 1997, 94, 12384–12389. [Google Scholar] [CrossRef] [PubMed]
- Cauza, E.; Peck-Radosavljevic, M.; Ulrich-Pur, H.; Datz, C.; Gschwantier, M.; Schoniger-Hekele, F.; Polli, C.; Rasoul-Rockenschaub, S.; Muller, C.; Wrba, F.; et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am. J. Gastroenterol. 2003, 98, 442–447. [Google Scholar] [CrossRef] [PubMed]
- Jin, F.; Qu, L.S.; Shen, X.Z. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: A meta-analysis. J. Exp. Clin. Cancer Res. 2010, 29, 18. [Google Scholar] [CrossRef] [PubMed]
- Jin, F.; Xiong, W.J.; Jing, J.C.; Feng, Z.; Qu, L.S.; Shen, X.Z. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: A systematic review. J. Cancer Res. Clin. Oncol. 2011, 137, 1095–1104. [Google Scholar] [CrossRef] [PubMed]
- Feder, J.N.; Penny, D.M.; Irrinki, A.; Lee, V.K.; Lebron, J.A.; Watson, N.; Tsuchihashi, Z.; Sigal, E.; Bjrorkman, P.J.; Schatzman, R.C. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. USA 1998, 95, 1472–1477. [Google Scholar] [CrossRef] [PubMed]
- Brandhagen, D.J.; Fairbanks, V.F.; Baldus, W.P.; Smith, C.I.; Kruckeberg, K.E.; Schaid, D.J.; Thibodeau, S.N. Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am. J. Gastroenterol. 2000, 95, 2910–2914. [Google Scholar] [CrossRef] [PubMed]
- Cassanelli, S.; Pignatti, E.; Montosi, G.; Garuti, C.; Mariano, M.; Campioli, D.; Carbonieri, A.; Baldini, E.; Pietrangelo, A. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J. Hepatol. 2001, 34, 523–528. [Google Scholar] [CrossRef]
- Fairbanks, V.F.; Brandhagen, D.J.; Thibodeau, S.N.; Snow, K.; Wollan, P.C. H63D is an haemochromatosis associated allele. Gut 1998, 43, 441–442. [Google Scholar] [CrossRef] [PubMed]
- Steinberg, K.K.; Cogswell, M.E.; Chang, J.C.; Caudill, S.P.; McQuillan, G.M.; Bowman, B.A.; Grummer-Strawn, L.M.; Sampson, E.J.; Khoury, M.J.; Gallagher, M.L. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001, 285, 2216–2222. [Google Scholar] [CrossRef] [PubMed]
- Kew, M.C. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett. 2009, 286, 38–43. [Google Scholar] [CrossRef] [PubMed]
- MacDonald, G.A.; Bridle, K.R.; Ward, P.J.; Walker, N.I.; Houglum, K.; George, D.K.; Smith, J.L.; Crawford, D.H.; Ramm, G.A. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J. Gastroenterol. Hepatol. 2001, 16, 599–606. [Google Scholar] [CrossRef] [PubMed]
- Puliyel, M.; Mainous, A.G., 3rd; Berdoukas, V.; Coates, T.D. Iron toxicity and its possible association with treatment of Cancer: Lessons from hemoglobinopathies and rare, transfusion-dependent anemias. Free Radic. Biol. Med. 2015, 79, 343–351. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Zhang, F. Iron homeostasis and tumorigenesis: Molecular mechanisms and therapeutic opportunities. Protein Cell 2015, 6, 88–100. [Google Scholar] [CrossRef] [PubMed]
- Abraham, B.K.; Justenhoven, C.; Pesch, B.; Harth, V.; Weirich, G.; Baisch, C.; Rabstein, S.; Ko, Y.D.; Bruning, T.; Fischer, H.P.; et al. Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1102–1107. [Google Scholar] [CrossRef] [PubMed]
- Altes, A.; Gimferrer, E.; Capella, G.; Barcelo, M.J.; Baiget, M. Colorectal cancer and HFE gene mutations. Haematologica 1999, 84, 479–480. [Google Scholar] [PubMed]
- Barton, J.C.; Bertoli, L.F.; Acton, R.T. HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer 2004, 4, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cardoso, C.S.; Araujo, H.C.; Cruz, E.; Afonso, A.; Mascarenhas, C.; Moutinho, J.; Lopes, C.; Medeiros, R. Haemochromatosis gene (HFE) mutations in viral-associated neoplasia: Linkage to cervical cancer. Biochem. Biophys. Res. Commun. 2006, 341, 232–238. [Google Scholar] [CrossRef] [PubMed]
- Dorak, M.T.; Burnett, A.K.; Worwood, M.; Sproul, A.M.; Gibson, B.E. The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia. Blood 1999, 94, 3957–3958. [Google Scholar] [PubMed]
- Gimferrer, E.; Nomdedeu, J.; Gich, I.; Barcelo, M.J.; Baiget, M. Prevalence of hemochromatosis related HFE gene mutations in patients with acute myeloid leukemia. Leuk. Res. 1999, 23, 597–598. [Google Scholar] [CrossRef]
- Gunel-Ozcan, A.; Alyilmaz-Bekmez, S.; Guler, E.N.; Guc, D. HFE H63D mutation frequency shows an increase in Turkish women with breast cancer. BMC Cancer 2006, 6, 37. [Google Scholar] [CrossRef] [PubMed]
- Kondrashova, T.V.; Neriishi, K.; Ban, S.; Ivanova, T.I.; Krikunova, L.I.; Smirkova, I.A.; Konova, M.V.; Taira, S.; Tsyb, A.F. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim. Biophys. Acta 2006, 1762, 59–65. [Google Scholar] [CrossRef] [PubMed]
- Macdonald, G.A.; Tarish, J.; Whitehall, V.J.; McCann, S.J.; Buttenshaw, R.L.; Johnson, A.G.; Young, J.; Leggett, B.A. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J. Gastroenterol. Hepatol. 1999, 14, 1188–1191. [Google Scholar] [CrossRef] [PubMed]
- Martinez di Montemuros, F.; Tavazzi, D.; Salsano, E.; Piepoli, T.; Pollo, B.; Fiorelli, G.; Finocchiaro, G. High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. Neurology 2001, 57, 1342. [Google Scholar] [CrossRef] [PubMed]
- Robinson, J.P.; Johnson, V.L.; Rogers, P.A.; Houlston, R.S.; Maher, E.R.; Bishop, D.T.; Thomas, H.J.; Tomlison, I.P.; Silver, A.R. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1460–1463. [Google Scholar] [CrossRef] [PubMed]
- Shaheen, N.J.; Silverman, L.M.; Keku, T.; Lawrence, L.B.; Rohifs, E.M.; Martin, C.F.; Galanko, J.; Sandler, R.S. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J. Natl. Cancer Inst. 2003, 95, 154–159. [Google Scholar] [CrossRef] [PubMed]
- Van der A, D.L.; van der Hel, O.; Roest, M.; van der Schouw, Y.T.; van Gils, C.H.; van Noord, P.A.; Peeters, P.H.M. Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands). Cancer Causes Control 2003, 14, 541–545. [Google Scholar] [CrossRef] [PubMed]
- Ellervik, C.; Birgens, H.; Tybjaerg-Hansen, A.; Nordestgaard, B.G. Hemochromatosis genotypes and risk of 31 disease endpoints: Meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007, 46, 1071–1080. [Google Scholar] [CrossRef] [PubMed]
- Chen, W.; Zhao, H.; Li, T.; Yao, H. HFE gene C282Y variant is associated with colorectal cancer in Caucasians: A meta-analysis. Tumour Biol. 2013, 34, 2255–2259. [Google Scholar] [CrossRef] [PubMed]
- Agudo, A.; Bonet, C.; Sala, N.; Munoz, X.; Aranda, N.; Fonseca-Nunes, A.; Clavel-Chapelton, F.; Boutron-Rault, M.C.; Vineis, P.; Panico, S.; et al. Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Carcinogenesis 2013, 34, 1244–1250. [Google Scholar] [CrossRef] [PubMed]
- Richie, J.P., Jr.; Kleinman, W.; Marina, P.; Abraham, P.; Wynder, E.L.; Muscat, J.E. Blood iron, glutathione, and micronutrient levels and the risk of oral cancer. Nutr. Cancer 2008, 60, 474–482. [Google Scholar] [CrossRef] [PubMed]
- Patel, B.P.; Rawal, U.M.; Rawal, R.M.; Shukla, S.N.; Patel, P.S. Tobacco, antioxidant enzymes, oxidative stress, and genetic susceptibility in oral cancer. Am. J. Clin. Oncol. 2008, 31, 454–459. [Google Scholar] [CrossRef] [PubMed]
- Novacek, G. Plummer-Vinson syndrome. Orphanet J. Rare Dis. 2006, 1, 36. [Google Scholar] [CrossRef] [PubMed]
- Pedersen, P.; Milman, N. Genetic screening for HFE hemochromatosis in 6,020 Danish men: Penetrance of C282Y, H63D, and S65C variants. Ann. Hematol. 2009, 88, 775–784. [Google Scholar] [CrossRef] [PubMed]
- Muscat, J.E.; Richie, J.P., Jr.; Thompson, S.; Wynder, E.L. Gender differences in smoking and risk for oral cancer. Cancer Res. 1996, 56, 5192–5197. [Google Scholar] [PubMed]
- Franco, E.L.; Kowalski, L.P.; Oliveira, B.V.; Curado, M.P.; Pereira, R.N.; Silva, M.E.; Fava, A.S.; Torloni, H. Risk factors for oral cancer in Brazil: A case-control study. Int. J. Cancer 1989, 43, 992–1000. [Google Scholar] [CrossRef] [PubMed]
- Ausubel, F.M.; Brent, R.; Kingston, R.; Moore, D.D.; Seidman, J.G.; Smith, J.A.; Struhl, K. Current Protocols in Molecular Biology; John Wiley and Sons: New York, NY, USA, 1989; Volume 1, pp. 2.1.1–2.1.3. [Google Scholar]
- Elahi, A.; Bendaly, J.; Zheng, Z.; Muscat, J.E.; Richie, J.P., Jr.; Schantz, S.P.; Lazarus, P. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003, 98, 872–880. [Google Scholar] [CrossRef] [PubMed]
- Brittenham, G. Spectrophotometric plasma iron determination from fingerpuncture specimens. Clin. Chim. Acta 1979, 91, 203–211. [Google Scholar] [CrossRef]
- Cook, J.D. An evaluation of adsorption methods for measurement of plasma iron-binding capacity. J. Lab. Clin. Med. 1970, 76, 497–506. [Google Scholar] [PubMed]
- Cook, J.D.; Lipschitz, D.A.; Miles, L.E.; Finch, C.A. Serum ferritin as a measure of iron stores in normal subjects. Am. J. Clin. Nutr. 1974, 27, 681–687. [Google Scholar] [PubMed]
- Davies, L.; Welch, H.G. Epidemiology of head and neck cancer in the United States. Otolaryngol. Head Neck Surg. 2006, 135, 451–457. [Google Scholar] [CrossRef] [PubMed]
- Altekruse, S.F.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Ruhl, J.; Howlader, N.; Tatalovich, Z.; Cho, H.; Mariotto, A.; et al. (Eds.) SEER Cancer Statistics Review, 1975–2007; National Cancer Institute: Bethesda, MD, USA; Available online: http://seer.cancer.gov/csr/1975_2007/ (accessed on 26 October 2015)Based on November 2009 SEER data submission, posted to the SEER web site, 2010.
- Canto, M.T.; Devesa, S.S. Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998. Oral Oncol. 2002, 38, 610–617. [Google Scholar] [CrossRef]
- Cann, C.I.; Fried, M.P.; Rothman, K.J. Epidemiology of squamous cell cancer of the head and neck. Otolaryngol. Clin. North Am. 1985, 18, 367–388. [Google Scholar] [PubMed]
- Hoffmann, D.; Hecht, S.S. Nicotine-derived N-nitrosamines and tobacco-related cancer: Current status and future directions. Cancer Res. 1985, 45, 935–944. [Google Scholar] [PubMed]
- Marshall, J.R.; Boyle, P. Nutrition and oral cancer. Cancer Causes Control 1996, 7, 101–111. [Google Scholar] [CrossRef] [PubMed]
- McCoy, G.D.; Wynder, E.L. Etiological and preventive implications in alcohol carcinogenesis. Cancer Res. 1979, 39, 2844–2850. [Google Scholar] [PubMed]
- Warnakulasuriya, S.; Sutherland, G.; Scully, C. Tobacco, oral cancer, and treatment of dependence. Oral. Oncol. 2005, 41, 244–260. [Google Scholar] [CrossRef] [PubMed]
- Winn, D.M. Diet and nutrition in the etiology of oral cancer. Am. J. Clin. Nutr. 1995, 61, 437S–445S. [Google Scholar] [PubMed]
- Wu, S.-H.; Lee, K.-W.; Chen, C.-H.; Lin, C.-C.; Tseng, Y.-M.; Ma, H.; Tsai, S.-M.; Tsai, L.-Y. Epistasis of oxidative stress-related enzyme genes on modulating the risks in oral cavity cancer. Clin. Chim. Acta 2010, 411, 1705–1710. [Google Scholar] [CrossRef] [PubMed]
- Chua, A.C.; Graham, R.M.; Trinder, D.; Olynyk, J.K. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 2007, 44, 413–459. [Google Scholar] [CrossRef] [PubMed]
- Ganz, T.; Nemeth, E. Regulation of iron acquisition and iron distribution in mammals. Biochim. Biophys. Acta 2006, 1763, 690–699. [Google Scholar] [CrossRef] [PubMed]
- Ammann, R.W.; Muller, E.; Bansky, J.; Schuler, G.; Hacki, W.H. High incidence of extrahepatic carcinomas in idiopathic hemochromatosis. Scand. J. Gastroenterol. 1980, 15, 733–736. [Google Scholar] [CrossRef] [PubMed]
- Rochette, J.; Le Gac, G.; Lassoued, K.; Ferec, C.; Robson, K.J. Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum. Genet. 2010, 128, 233–248. [Google Scholar] [CrossRef] [PubMed]
- Rossi, E.; Olynyk, J.K.; Jeffrey, G.P. Clinical penetrance of C282Y homozygous HFE hemochromatosis. Expert Rev. Hematol. 2008, 1, 205–216. [Google Scholar] [CrossRef] [PubMed]
- Matthews, A.L.; Grimes, S.J.; Wiesner, G.L.; Acheson, L.S. Clinical consult: Iron overload--hereditary hemochromatosis. Prim. Care 2004, 31, 767–770, xii-xiii. [Google Scholar] [CrossRef] [PubMed]
- Whitfield, J.B.; Cullen, L.M.; Jazwinska, E.C.; Powell, L.W.; Heath, A.C.; Duffy, D.L.; Martin, N.G. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am. J. Hum. Genet. 2000, 66, 1246–1258. [Google Scholar] [CrossRef] [PubMed]
- Torti, S.V.; Torti, F.M. Iron and ferritin in inflammation and cancer. Adv. Inorg. Biochem. 1994, 10, 119–137. [Google Scholar] [PubMed]
- Weiss, G.; Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352, 1011–1023. [Google Scholar] [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jones, N.R.; Ashmore, J.H.; Lee, S.Y.; Richie, J.P.; Lazarus, P.; Muscat, J.E. Association Studies of HFE C282Y and H63D Variants with Oral Cancer Risk and Iron Homeostasis Among Whites and Blacks. Cancers 2015, 7, 2386-2396. https://doi.org/10.3390/cancers7040898
Jones NR, Ashmore JH, Lee SY, Richie JP, Lazarus P, Muscat JE. Association Studies of HFE C282Y and H63D Variants with Oral Cancer Risk and Iron Homeostasis Among Whites and Blacks. Cancers. 2015; 7(4):2386-2396. https://doi.org/10.3390/cancers7040898
Chicago/Turabian StyleJones, Nathan R., Joseph H. Ashmore, Sang Y. Lee, John P. Richie, Philip Lazarus, and Joshua E. Muscat. 2015. "Association Studies of HFE C282Y and H63D Variants with Oral Cancer Risk and Iron Homeostasis Among Whites and Blacks" Cancers 7, no. 4: 2386-2396. https://doi.org/10.3390/cancers7040898